Rankings
▼
Calendar
RCUS
Arcus Biosciences, Inc.
$2B
Q3 2022 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$33M
+248.8% YoY
Gross Profit
$33M
100.0% margin
Operating Income
-$70M
-212.1% margin
Net Income
-$65M
-197.0% margin
EPS (Diluted)
$-0.84
QoQ Revenue Growth
+22.2%
Cash Flow
Operating Cash Flow
-$81M
Free Cash Flow
-$82M
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$1.4B
Total Liabilities
$695M
Stockholders' Equity
$699M
Cash & Equivalents
$218M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$33M
$9M
+248.8%
Gross Profit
$33M
$9M
+248.8%
Operating Income
-$70M
-$78M
+10.4%
Net Income
-$65M
-$78M
+16.6%
Revenue Segments
License and Development Services for All Gilead Programs
$24M
71%
Gilead Access Rights
$8M
25%
Taiho Access Rights
$2M
5%
← FY 2022
All Quarters
Q4 2022 →
RCUS Q3 2022 Earnings — Arcus Biosciences, Inc. Revenue & Financial Results | Market Cap Arena